Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An Open Label Randomized Phase II Trial With Durvalumab Following Stereotactic Body Radiotherapy (SBRT) in Patients With Stage I Non-small Cell Lung Cancer (NSCLC)

NCT03446547 is registered in ClinicalTrials.gov with Vastra Gotaland Region as lead sponsor.

NCT NCT03446547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03446547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An Open Label Randomized Phase II Trial With Durvalumab Following Stereotactic Body Radiotherapy (SBRT) in Patients With Stage I Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Vastra Gotaland Region
Phase
Phase 2
Overall status
Completed
Start date
December 4, 2017
Completion date
October 1, 2025
Enrollment
106 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc, stage i